These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30567283)

  • 1.
    Ferranti M; Tadiotto Cicogna G; Sattin A; Alaibac M
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
    Russo I; Miotto S; Saponeri A; Alaibac M
    Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of severe refractory pemphigus vulgaris with rituximab].
    Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM
    Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rituximab as treatment for refractory pemphigus in Mexican patients].
    Cruz-Meza S; Ruiz-Arriaga LF; Barrón-Tapia MT; Estrada-Aguilar L
    Rev Alerg Mex; 2021; 68(1):7-11. PubMed ID: 34148324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab Therapy for Childhood Pemphigus Vulgaris.
    Kincaid L; Weinstein M
    Pediatr Dermatol; 2016; 33(2):e61-4. PubMed ID: 26765543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature.
    Mistry BD; Leis M; Lee DM; Levy R
    Pediatr Dermatol; 2022 Nov; 39(6):960-966. PubMed ID: 35871636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
    Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab administration in a patient with pemphigus vulgaris following reactivation of occult hepatitis B virus infection.
    Tavakolpour S; Soori T; Noormohammadpour P; Balighi K; Mahmoudi H; Daneshpazhooh M
    Dermatol Online J; 2017 Jun; 23(6):. PubMed ID: 28633752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into Citrobacter freundii sepsis in neonates.
    Chen D; Ji Y
    Pediatr Int; 2019 Apr; 61(4):375-380. PubMed ID: 30325560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
    Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
    Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.
    Corral IS; Freitas TH; Aquino RT; Koller DA; Magliari ME; Muller H
    An Bras Dermatol; 2013; 88(4):639-42. PubMed ID: 24068143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
    Morrison LH
    J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study.
    Aryanian Z; Balighi K; Daneshpazhooh M; Karamshahi E; Hatami P; Goodarzi A; Tajalli M; Vance TM
    Int Immunopharmacol; 2021 Jul; 96():107755. PubMed ID: 34162136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RITUXIMAB FOR THE TREATMENT OF PEMPHIGUS - A REVIEW OF RECENT STUDIES AND PERSONAL EXPERIENCE FROM THE RABIN MEDICAL CENTER AND THE SHEBA MEDICAL CENTER].
    Mimouni D; Baum S
    Harefuah; 2020 Jan; 159(1):31-33. PubMed ID: 31930805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
    Antonucci A; Negosanti M; Tabanelli M; Varotti C
    J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of a case of pediatric pemphigus vulgaris treated with rituximab.
    Didona D; Paolino G; Donati M; Caposeina D; Calvieri S; Didona B
    Acta Dermatovenerol Croat; 2014; 22(4):288-90. PubMed ID: 25580789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.